(3-AMINOOXALYL-1-BENZYL-2-ETHYL-1H-INDOL-4-YLOXY)-ACETIC ACID METHYL ESTER

Varespladib methyl (also known as A-002, formerly LY333013 and S-3013) is a secretory phospholipase A2 (sPLA2) inhibitor formerly under development by Anthera Pharmaceuticals as a treatment for acute coronary syndrome (ACS). Varespladib methyl is an orally bioavailable prodrug of the molecule varespladib. From 2006 to 2012, varespladib methyl was under active investigation by Anthera Pharmaceuticals as a potential therapy for several inflammatory diseases, including acute coronary syndrome. In March 2012, Anthera halted further investigation of varespladib per a recommendation from an independent Data Safety Monitoring Board.